| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 18 | — | 17.8x | Bottom tier | |
Growth | 85 | 42.7% | 7.1% | Top tier | |
Quality | 47 | -37.5% | 4.5% | Around median | |
Safety | 26 | — | 2.6x | Bottom tier | |
Capital Return | 15 | — | 2.12% | Bottom tier | |
Momentum | 98 | 163.3% | 2.9% | Top tier | |
Sentiment | 75 | 12 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Guardant Health develops blood- and tissue-based tests for precision medicine through its Smart Platform and targets four areas: therapy selection, cancer recurrence monitoring, cancer screening, and multi-disease detection. The company generates revenue from its oncology business, which includes Guardant360 Liquid, Guardant360 Tissue, and Reveal; from Biopharma & Data services and companion diagnostic partnerships; and from the Shield colorectal cancer screening test. Management says its data repository includes more than 1.3 million patient tests and more than 700 thousand epigenomic profiles covering more than 100 tumor types, and supports InfinityAI applications and drug discovery programs.
In fiscal Q2 2026, revenue reached $335.0 million, up 44% year over year, and gross profit was $219.0 million, equivalent to a GAAP gross margin of approximately 65.4%, while the company recorded a net loss of $120.1 million and a loss per share of $0.90, according to EDGAR data. Revenue disclosed on the call was split between $219 million from oncology, up 38%, $61 million from Biopharma & Data, up 9%, and $53 million from Shield, compared with $15 million a year earlier. On a non-GAAP basis, gross margin was 67% versus 66% a year earlier, but adjusted earnings before interest, taxes, depreciation, and amortization loss widened to $56 million from $52 million.
The results reflect strong growth in test volumes alongside continued high spending to expand the screening business. Oncology test volume rose 63% to approximately 104 thousand tests, Guardant360 Liquid volume increased by more than 30%, and Reveal growth exceeded 100%, while the company performed approximately 66 thousand Shield tests versus 16 thousand in the comparable quarter. Meanwhile, non-GAAP operating expenses reached $288 million, up 34%, and free cash flow burn reached $70 million during the quarter.
The average analyst price target is $193.07, within a wide range of $150 to $210, and the stock has a consensus “Buy” rating; the average target is also approximately 9.3% above the 52-week high of $176.58. With no usable price-to-earnings ratio due to continued losses, the valuation depends heavily on achieving fiscal 2026 growth guidance of between 36% and 38%, reducing cash burn, and reaching cash flow breakeven by the end of fiscal 2027, while the wide range of targets and the 52-week range of $53.4 to $176.58 highlight the extent of the uncertainty.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
Fiscal Q2 2026 revenue reached approximately $335 million, up 44% year over year. Oncology revenue grew 38% to $219 million as volume rose 63% to approximately 104 thousand tests, while Biopharma & Data posted a record $61 million. Shield generated revenue of $53 million from approximately 66 thousand tests, compared with $15 million and 16 thousand tests in the comparable period.
Shield is an FDA-approved blood test for colorectal cancer screening, and its volume reached approximately 66 thousand tests in fiscal Q2 2026 versus 16 thousand a year earlier. The test was added to the American Cancer Society guidelines in May 2026, and UnitedHealth Group began covering it for average-risk adults aged 45 and older on August 1, 2026. The company estimates that approximately 70 million people are now covered, and it raised its fiscal 2026 guidance to between 270 thousand and 285 thousand Shield tests.
The company continues to record losses, with a net loss of approximately $120.1 million in fiscal Q2 2026 according to EDGAR and a loss per share of $0.90. The earnings report published on July 31, 2026, showed an adjusted loss of $0.42 per share, which was larger than the analyst estimate of $0.40 but slightly better than the loss of $0.44 a year earlier. Free cash flow burn reached $70 million in the quarter, while management expects burn of between $195 million and $205 million during fiscal 2026.
Automated analysis for informational purposes only — not investment advice.
Guardant360 Liquid CDx received FDA approval in May 2026, and its phased rollout in the United States began in June 2026. The company describes it as the only FDA-approved liquid test that integrates genomic and epigenomic content, with 100 times more content than the previously approved CDx product. Guardant Health is targeting ADLT designation in the first half of fiscal 2027, and management expects a Medicare price of $8,455 upon obtaining it, compared with $5,000 currently, with other payers transitioning their pricing over a period that may extend from 12 to 24 months.
Reveal was the fastest-growing oncology product in fiscal Q2 2026, with volume growth exceeding 100% year over year for the third consecutive quarter. The product supports residual disease monitoring and treatment response monitoring, and the company says its result turnaround time is five days. Guardant Health is targeting the launch of Reveal Ultra later in fiscal 2026 and has stated that the test consistently achieved detection limits below one part per million during development, but some MolDX coverage decisions remain under review.
Management raised its fiscal 2026 revenue guidance to between $1.34 billion and $1.36 billion, equivalent to growth of between 36% and 38%. It expects approximately 30% growth in oncology revenue and 50% growth in oncology volumes, with Shield revenue guidance of between $218 million and $230 million. It also maintained its non-GAAP gross margin target at 64% to 65% and affirmed its commitment to achieving company-wide cash flow breakeven by the end of fiscal 2027.
